1378387-81-5

Basic information

• Product Name: 1-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-Ethanone
• Synonyms: 1-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-Ethanone;Ethanone, 1-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-;7-Bromo-2-(chloroacetyl)-9,9-difluorofluorene;1-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-2-chloroethan-1-one
• CAS NO: 1378387-81-5
• Molecular Formula: C15H8BrClF2O
• Molecular Weight: 357.5772264
• EINECS: 1592732-453-0
• Product Categories: API
• Mol File: 1378387-81-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 183.0 to 187.0 °C
• Boiling Point: 428.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.69±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-Ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-Ethanone(1378387-81-5)
• EPA Substance Registry System: 1-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-Ethanone(1378387-81-5)

Safety Data

• Hazardous Substances Data: 1378387-81-5(Hazardous Substances Data)

Usage

General Description

1-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-chloro-ethanone is a compound consisting of a fluorene ring with a bromine and two fluoro substituents at the 7 and 9 positions, and a chloroethanone group attached to the fluorene ring. This chemical is commonly used in organic synthesis and pharmaceutical research due to its unique structure and reactivity. It has the potential to be utilized in the development of new drugs and materials, and it can also be employed as a reagent in various chemical reactions. Additionally, its specific structural features could allow for selective functionalization and manipulation, making it a valuable building block in the synthesis of complex organic molecules.

Upstream product

• 493028-83-4 4-bromobiphenyl-2-carboxylic acid methyl ester 
• 21740-00-1 5-bromo-2-iodo-benzoic acid 
• 181765-86-6 5-bromo-2-iodo-benzoic acid methyl ester 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 69200-18-6 4-bromo-[1,1′-biphenyl]-2-carboxylic acid 
• 86233-09-2 2-benzyl-4-bromoaniline 
• 103-88-8 4-bromoacetanilide 
• 106-40-1 4-bromo-aniline 
• 79-04-9 chloroacetyl chloride 
• 98216-25-2 2-bromo-7-chloroacetylfluorene 
• 86-73-7 9H-fluorene 
• 1229603-71-7 2,7-dibromo-9,9-difluoro-9H-fluorene 
• 99515-75-0 2-bromo-9,9-dichlorofluorene 
• 3096-56-8 2-bromofluoren-9-one 

Downstream Products

• 1499193-61-1 (S)-6-(2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl) 5-tert-butyl 5-azaspiro[2.4]heptane-5,6-dicarboxylate 
• 1256393-27-7 3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1256388-49-4 6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carboxylic acid benzyl ester 
• 1256388-48-3 5-aza-spiro[2.4]heptane-5,6-dicarboxylic acid 5-benzyl ester 6-[2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxo-ethyl] ester 

Relevant articles and documents

Preparation method of key intermediate of anti-hepatitis C drug ledipasvir

The invention provides a preparation method of a key intermediate 1-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-chloroethanone. The method comprises the steps as follows: 2-amino-5-bromobenzoic acid is taken as a raw material, and subjected to diazotization, iodination,synthesis of 5-bromo-2-iodobenzoic acid, methylation, coupling reaction with phenylboronic acid, ester hydrolysis, acyl chlorination,intramolecular Friedel-Crafts alkylation, carbonyl reduction, iodization, fluorination and final reaction with 2-chloro-N-methoxy-N-methylacetamide to prepare the target product. The process adopts easily available starting raw materials, is low in price and free of hazardous process and has mild reaction conditions..

Anti-hepatitis c pharmaceutical intermediates

The invention provided a compound represented by the formula I and a method utilizing the compound to prepare an anti hepatitis C drug. The preparation method is simple and economic, and is capable of being applying to industrial production, so the preparation of an anti hepatitis C drug may be achieved. The formula I is represented in the description, wherein the R represents fluorine or hydrogen, and the n is equal to 2 or 3.

Ledipasvir preparation method

The invention discloses a Ledipasvir preparation method. The Ledipasvir preparation method includes steps: (1) Ledipasvir intermediate product 1-LD-B preparation; (2) Ledipasvir intermediate product 2-LD-E preparation; (3) Ledipasvir intermediate product 3-LD-F preparation; (4) Ledipasvir intermediate product 4-LD-J preparation; (5) Ledipasvir intermediate product 5-LD-L preparation; (6) Ledipasvir-LD-Q preparation. The Ledipasvir preparation method has advantages of technical maturity and stability, product quality stability, safety and reliability in production process and suitableness for industrial production.